Marrone Bio Innovations (MBII) Getting Somewhat Favorable Media Coverage, Report Shows

Media stories about Marrone Bio Innovations (NASDAQ:MBII) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marrone Bio Innovations earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the basic materials company an impact score of 46.1419402737771 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Get Marrone Bio Innovations alerts: Average True Range (ATR 14) to Track Pennsylvania Real Estate Investment Trust (NYSE:PEI), Marrone Bio … (stocksnewspoint.com) Global Bionematicides Market Size 2018 �� 2023: Bayer Cropscience AG, T. Stanes & Company Limited, Marrone Bio … (thechronicleindia.com) Foreshadowing Stocks: Navios Maritime Acquisition Corporation (NYSE:NNA), Marrone Bio Innovations, Inc. (NASDAQ … (journalfinance.net) Global Biocontrol Agents Market Analysis Report 2018: Koppert Biological Systems BV, Monsanto Company Inc … (thebusinesstactics.com) Global Bioherbicides Market Size 2018 �� 2023: Verdesian Life Sciences, Marrone Bio Innovations Inc, Emery … (thechronicleindia.com)

Shares of MBII traded up $0.01 during trading hours on Thursday, reaching $1.91. 2,820 shares of the company traded hands, compared to its average volume of 627,114. The company has a quick ratio of 1.76, a current ratio of 2.63 and a debt-to-equity ratio of 1.40. The firm has a market cap of $189.89 million, a P/E ratio of -1.79 and a beta of -0.55. Marrone Bio Innovations has a fifty-two week low of $0.85 and a fifty-two week high of $3.39.

Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, May 10th. The basic materials company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The company had revenue of $4.32 million for the quarter. equities analysts expect that Marrone Bio Innovations will post -0.16 EPS for the current fiscal year.

A number of research analysts recently weighed in on MBII shares. Zacks Investment Research raised Marrone Bio Innovations from a “sell” rating to a “hold” rating in a report on Friday, May 4th. ValuEngine raised Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. BidaskClub lowered Marrone Bio Innovations from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 12th. Jefferies Financial Group reissued a “hold” rating and issued a $1.55 target price on shares of Marrone Bio Innovations in a report on Wednesday, March 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Marrone Bio Innovations in a report on Tuesday, May 15th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $2.08.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.